BOSTON & BIRMINGHAM, United Kingdom--(BUSINESS WIRE)--Neutron Therapeutics, a leading developer of accelerator-based neutron systems for targeted radiation therapy of solid tumors, today announced ...
Management provided Q2 2025 revenue guidance between $130 million and $140 million, reflecting anticipated growth from both launch services and space systems. Gross margins for Q2 are projected in the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results